Castle biosciences inc.

Castle Biosciences is a pioneer in this field of spatial biology. Our biologically aware AI platform delivered Tissue Cypher® to the clinic, the world’s first precision medicine test to predict the risk of developing esophageal cancer in Barrett’s Esophagus patients – one of the world’s deadliest cancers. FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced data from a study showing ...Operating Status Active. Last Funding Type Post-IPO Equity. Legal Name Castle Biosciences, Inc. Stock Symbol NASDAQ:CSTL. Company Type For Profit. Contact Email [email protected]. Phone Number 602-535-1997. Castle Biosciences is a biotech company that develops and validates diagnostic tests and technologies for the treatment of cancer.Castle’s three-year financial targets include anticipated total revenue of $255-$330 million and anticipated net operating cash flow positivity for the year ending December 31, 2025Castle Creek Biosciences. Matthew Gantz is President and Chief Executive Officer of Castle Creek Biosciences, Inc., and a member of the company’s Board of Directors. An accomplished life sciences executive with more than 25 years of experience in the specialty biopharmaceutical and medical device industries, Mr. Gantz previously served as ...

If you're a new customer to Castle Biosciences, please call us when ordering a test. If a returning customer, you can use the requisition form.

Castle Biosciences, Inc. (NASDAQ:CSTL) announced its quarterly earnings results on Sunday, November, 7th. The company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by $0.13. The firm earned $23.48 million during the quarter, compared to the consensus estimate of $23.66 million.

Oct 25, 2023 · Castle Biosciences Inc’s price is currently down 25.04% so far this month. During the month of October, Castle Biosciences Inc’s stock price has reached a high of $16.84 and a low of $12.07. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26. Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced upcoming presentations on two of its skin cancer gene expression profile (GEP) tests at the 2022 American Academy of Dermatology (AAD) Annual Meeting, being held in Boston, March 25-29, 2022. ...NEW YORK, Aug. 2, 2013 /PRNewswire/ -- Castle Biosciences Inc. announced that data from studies of its DecisionDx-Melanoma test are being presented today at the Summer Academy Meeting of the ...Castle Biosciences Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. View CSTL financial statements in full.MyPath Melanoma has over 35,000 clinically resulted cases and 9 publications including validation to outcomes. DiffDx-Melanoma offers a neural network, artificial intelligence-designed algorithm with a low rate of intermediate results. The test was validated in cutaneous melanocytic lesions to accurately differentiate between benign and ...

Overview. Castle Biosciences is improving health through our innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating …

Castle Biosciences announced that it has completed its acquisition of AltheaDx, Inc. Castle Biosciences Completes Acquisition of AltheaDx Acquisition expands Castle’s estimated U.S. TAM by ...

Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. DecisionDx-Melanoma is performed in Castle Biosciences’ CAP accredited, CLIA certified laboratory using formalin-fixed, paraffin embedded (FFPE) primary tumor tissue from either a biopsy or excision. Castle Biosciences is a molecular diagnostics company that provides tumor-specific information for improved treatment decisions and patient ...Stock analysis for Castle Biosciences Inc (CSTL:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Board Chairman. Daniel M. Bradbury has served as a member our board of directors since September 2012, and as chairman of our board of directors since September 2014. Mr. Bradbury is co-founder and Executive Chairman of Equillium, Inc., a publicly traded biotechnology company, where he also served as its CEO from June 2018 until January 2020 ...Castle Biosciences. Manufacturing · Texas, United States · 342 Employees. Castle Biosciences develops and commercializes diagnostic and prognostic tests for dermatologic cancers. Castle Biosciences is headquartered in Friendswood, Texas with operations in Phoenix, Arizona. Read More. View Company Info for FreeDeciding the frequency and intensity of follow-up and surveillance. DecisionDx-SCC is performed on formalin-fixed, paraffin embedded (FFPE) primary tumor tissue from either a biopsy or excision. Castle Biosciences is a molecular diagnostics company that provides tumor-specific information for improved treatment decisions and patient outcomes.

Apr 4, 2022 · Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire AltheaDx, Inc. (AltheaDx). AltheaDx is a commercial-stage molecular diagnostics company specializing in the field of pharmacogenomics (PGx) testing services that ... Castle Creek Biosciences. Matthew Gantz is President and Chief Executive Officer of Castle Creek Biosciences, Inc., and a member of the company’s Board of Directors. An accomplished life sciences executive with more than 25 years of experience in the specialty biopharmaceutical and medical device industries, Mr. Gantz previously served as ...1 Jun 2023 ... NEW YORK – Medicare Administrative Contractor Wisconsin Physicians Service Insurance Corporation has released a proposed local coverage ...7 Apr 2021 ... Product details ... Do you want to earn up to a 1117163% annual return on your money by two trades per day on Castle Biosciences Inc CSTL Stock?Also on June 6, 2023, the Reporting Person transferred 149,000 shares of Castle Biosciences, Inc. common stock to the DJM Grantor Retained Annuity Trust No. 5 of which the Reporting Person is trustee and beneficiary. 4. Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the …Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers.Castle Biosciences is a molecular diagnostics company that provides tumor-specific information for improved treatment decisions and patient outcomes. Skip to content. COVID-19 Response. Customer Service: 866-788-9007. CLINICIAN PORTAL. ORDER TEST. COVID-19 Response. ORDER TEST.

DecisionDx-Melanoma is a validated 31-gene expression profile (GEP) test that was developed to identify the risk of recurrence or metastasis including the likelihood of sentinel lymph node positivity for patients with stage I, II, or III melanoma and inform patient management decisions. The DecisionDx-Melanoma test accurately and independently ...

Nov 2, 2023 · Overview. Castle Biosciences is improving health through our innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating the personalized information our tests provide. Castle Biosciences is a pioneer in this field of spatial biology. Our biologically aware AI platform delivered Tissue Cypher® to the clinic, the world’s first precision medicine test to predict the risk of developing esophageal cancer in Barrett’s Esophagus patients – one of the world’s deadliest cancers. Castle Biosciences continues to pursue deployment across multiple therapeutic areas.2,091.70 +34.50(+1.68%) Castle Biosciences, Inc. (CSTL) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 19.97 -0.02 (-0.10%) At close: 04:00PM EST 20.35 +0.38 (+1.90%) After...SEC Filings. Select Year: Filter filing type: Date Filing Type Filing Description Download / View. 11/22/2023. 144/A. Amended report of proposed sale of securities. 11/22/2023. 4. Statement of Changes in Beneficial Ownership.Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma ...John C. Cheneval is Executive Director-Business Development at Castle Biosciences, Inc. In his past career he was Vice President-Pharma Partnerships at HTG Molecular Diagnostics, Inc. and Executive...

CASTLE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 77-0701774 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 820 S. Friendswood Drive, Suite 201, Friendswood, Texas 77546 (Address of principal executive offices) (Zip Code) (866) 788-9007

THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of September 15, 2008 (the “Effective Date”) by and between Castle Biosciences, Inc., a Delaware corporation (the “Company”), and Kristen Oelschlager (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”).

Castle Biosciences, Inc. (NASDAQ:CSTL) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET. Company Participants. Camilla Zuckero - Vice President, Investor Relations and Corporate Affairs.DecisionDx-Melanoma (Castle Biosciences Inc [which also provided funding]) Observational, retrospective cohort of archival specimens; multicenter (n = 16), hospital and community based; patients with resected stage I-III melanoma with minimum of 5 y of follow-up if no recurrence: Nonprobability, convenience (2000-2014)Founder, President and CEO. Derek J. Maetzold founded Castle Biosciences in September 2007 and has served as our President, Chief Executive Officer and as a member of our board of directors since inception. Previously, Mr. Maetzold held leadership roles at Encysive Pharmaceuticals, Schering-Plough Corporation (now Merck), Integrated ...C/O CASTLE BIOSCIENCES, INC. 505 S. FRIENDSWOOD DRIVE, SUITE 401 (Street) FRIENDSWOOD: TX: 77546 (City) (State) (Zip) 2. Issuer Name and Ticker or Trading Symbol CASTLE BIOSCIENCES INC [ CSTL] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X: Director:Overview. Castle Biosciences is improving health through our innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating …Castle Biosciences (CSTL-0.50%) stock was absolutely crushing it on Friday, with shares skyrocketing 54.4% as of 11:47 a.m. ET. The huge gain came after Novitas, a regional Medicare administrative ...Castle Biosciences created a tissue repository to enable all DecisionDx-UM patients to have access to their own tumor tissue for future use. This could include taking advantage of targeted treatments, clinical trials, and further prognostic testing as they become available. Castle Biosciences is a molecular diagnostics company that provides ...Shares of Castle Biosciences ( CSTL 0.15%) closed this week down 12.6% for the week, after being down as much as 18.3% for the week, according to data provided by S&P Global Market Intelligence ...Operating Status Active. Last Funding Type Post-IPO Equity. Legal Name Castle Biosciences, Inc. Stock Symbol NASDAQ:CSTL. Company Type For Profit. Contact Email [email protected]. Phone Number 602-535-1997. Castle Biosciences is a biotech company that develops and validates diagnostic tests and technologies for the treatment of cancer.Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes. Also on June 6, 2023, the Reporting Person transferred 149,000 shares of Castle Biosciences, Inc. common stock to the DJM Grantor Retained Annuity Trust No. 5 of which the Reporting Person is trustee and beneficiary. 4. Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the …

Castle Biosciences, Inc is an Affirmative Action and Equal Opportunity Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability.Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET. Company Participants. Camilla Zuckero - Vice President, Investor Relations and Corporate Affairs.Instagram:https://instagram. who are united medicare advisorsotcmkts elcrcheapest motorcycle insurance azms earning This Registration Statement on Form S-8 is being filed by Castle Biosciences, Inc. (the “Registrant”) for the purpose of registering (i) an additional 1,327,684 shares of the Registrant’s Common Stock, $0.001 par value per share (“Common Stock”), under the Registrant’s 2019 Equity Incentive Plan (the “2019 Plan”), pursuant to the provisions of … worth of a 1921 silver dollartarget bk Belgium, a country known for its rich history, stunning architecture, and vibrant culture, offers a plethora of attractions for visitors to explore. From medieval castles to modern art galleries, Belgium has something for everyone. crowdstrike rating Apr 4, 2022 · Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire AltheaDx, Inc. (AltheaDx). AltheaDx is a commercial-stage molecular diagnostics company specializing in the field of pharmacogenomics (PGx) testing services that ... Nov 9, 2023 · Castle Biosciences Inc’s price is currently up 9.67% so far this month. During the month of November, Castle Biosciences Inc’s stock price has reached a high of $19.36 and a low of $15.28. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26. Vice President, Investor Relations & Corporate Affairs. See full bio. Castle Biosciences is a molecular diagnostics company that provides tumor-specific information for improved treatment decisions and patient outcomes.